It follows concern in numerous countries that products might contain an impurity that has been linked to cancer.
The four that are recalled are Zantac 150mg/10ml Syrup, Zantac 50mg/2ml Injection, Zantac 150mg Tablets, and Zantac 300mg Tablets.
But patients must keep taking their prescribed medicine, officials advise.
The Medicines and Healthcare Products Regulatory Agency (MHRA) stated that the health risk of discontinuing the medicine is more than the potential risk presented by the contaminant N-nitrosodimethylamine (NDMA).
Anyone who is worried about taking their medication should speak to their doctor or pharmacist.
What is the recall about?
NDMA has been classified as a likely human carcinogen (a substance that can cause cancer) on the basis of animal studies. It is present in some foods and in water supplies but does not pose danger or cause harm when ingested in very low levels.
The MHRA has requested manufacturers to quarantine all commodities which may contain the active pharmaceutical ingredient (API) that is potentially affected by this issue.
The four in the recall are made by GlaxoSmithKline (GSK).
Over-the-counter products (Zantac 75 Relief (PL 02855/0081 [GSL]) and Zantac 75 Tablets (PL 02855/0082 [P]), that are available for people to buy in pharmacies without the need of a prescription, are produced by a different company and are not affected by the recall.
The MHRA is investigating other ranitidine medicines which might also be affected and will provide updates soon.